OTC Daily Oral Contraceptive Proposal In US Packs Promise Of Access, But Peril Of Single Option

Discussion of whether progestin-only formulation will be approved for OTC sales and succeed in the US nonprescription market perhaps has been overshadowed by expectations of political pressures affecting FDA’s evaluation and decision after HRA submitted its NDA.